Beta Bionics (BBNX) Stock Overview
A commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
BBNX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Beta Bionics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.04 |
| 52 Week High | US$32.71 |
| 52 Week Low | US$8.80 |
| Beta | 0 |
| 1 Month Change | 15.70% |
| 3 Month Change | 61.23% |
| 1 Year Change | -3.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.73% |
Recent News & Updates
Recent updates
Beta Bionics: Mint Clearance Marks The Shift Toward A Multi-Engine Growth Story
Summary Beta Bionics (BBNX) is evolving into a multi-product, platform-driven diabetes franchise with the FDA-cleared Mint patch pump launching in 1Q27. Mint expands BBNX's addressable market, accelerates pharmacy channel mix, and, alongside 3D Intelligence, strengthens ecosystem retention and differentiation. 2026 revenue guidance was cut due to demand deferral, but this sets up a stronger 2027 ramp as patients await Mint’s launch. A $150M equity raise funds Mint’s rollout and expansion, balancing near-term dilution against de-risked growth; valuation reflects both upside and execution risk. Read the full article on Seeking Alpha
BBNX: Clearer Type 2 And Closed Loop Timelines Will Drive Future Confidence
The analyst price target for Beta Bionics is now $21.67, up from $19.80, as analysts point to clearer timelines for Type 2 diabetes and fully closed loop indications, along with ongoing survey evidence of iLet adoption and expectations for the company’s entry into the patch pump market. Analyst Commentary Recent Street research on Beta Bionics shows a range of views on valuation and execution, with several firms updating price targets as they reassess the company’s pipeline, expected patch pump entry, and timing for Type 2 diabetes and fully closed loop indications.Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...BBNX: I Expect Real World Data Transparency Will Drive Future Confidence
Analysts now place the fair value estimate for Beta Bionics at about $19.80 per share, down from $31.30. This comes even as recent Street research has lifted various published price targets into a $13 to $22 range on survey work pointing to continued iLet momentum and updated views on medtech valuations.
BBNX: Regulatory Recalls And Legal Probe Will Drive A More Cautious Outlook
Analysts have reset the fair value estimate for Beta Bionics to $13.00 from $25.00, reflecting a series of reduced price targets across the Street that weigh a lower assumed future P/E multiple alongside updated views on revenue growth and profit margins, even as some highlight supportive FDA feedback and an earlier expected Mint launch timeline. Analyst Commentary Recent Street research on Beta Bionics points to a mixed backdrop, with a cluster of reduced price targets alongside some more constructive commentary tied to regulatory progress and the Mint launch timeline.
BBNX: Mint Launch Timeline And Regulatory Progress Will Drive Future Upside
The analyst price target for Beta Bionics has been revised lower by approximately $10.81. This change reflects a series of reduced targets across several firms as analysts incorporate updated medtech sector valuations and refreshed expectations for the company’s growth, profitability, and future P/E assumptions.Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Beta Bionics, Inc.'s (NASDAQ:BBNX) Popularity With Investors Under Threat As Stock Sinks 58%
The Beta Bionics, Inc. ( NASDAQ:BBNX ) share price has fared very poorly over the last month, falling by a substantial...Pharmacy-Driven Diabetes Technology Adoption Will Support A Stronger Long-Term Outlook
Catalysts About Beta Bionics Beta Bionics develops automated insulin delivery systems aimed at simplifying diabetes management for people using insulin pumps. What are the underlying business or industry changes driving this perspective?We're Hopeful That Beta Bionics (NASDAQ:BBNX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Beta Bionics, Inc. (NASDAQ:BBNX) Looks Just Right With A 35% Price Jump
Despite an already strong run, Beta Bionics, Inc. ( NASDAQ:BBNX ) shares have been powering on, with a gain of 35% in...Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Beta Bionics: Slowing Down Or Being Conservative?
Summary Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure. With substantial net cash holdings, the stock remains interesting if the guidance is conservative, offering potential upside given the current low valuation. Read the full article on Seeking AlphaBeta Bionics: A Sugar Rush For This IPO
Summary Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company’s iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years. While the growth is compelling, risks include competition, reliance on partners, and the single-product nature, making me cautious about initiating a position now. Read the full article on Seeking AlphaShareholder Returns
| BBNX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 31.7% | 0.4% | -0.1% |
| 1Y | -3.8% | -16.3% | 11.9% |
Return vs Industry: BBNX exceeded the US Medical Equipment industry which returned -16.3% over the past year.
Return vs Market: BBNX underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| BBNX volatility | |
|---|---|
| BBNX Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BBNX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BBNX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 422 | Sean Saint | www.betabionics.com |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.
Beta Bionics, Inc. Fundamentals Summary
| BBNX fundamental statistics | |
|---|---|
| Market cap | US$1.15b |
| Earnings (TTM) | -US$72.97m |
| Revenue (TTM) | US$119.01m |
Is BBNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBNX income statement (TTM) | |
|---|---|
| Revenue | US$119.01m |
| Cost of Revenue | US$49.61m |
| Gross Profit | US$69.40m |
| Other Expenses | US$142.38m |
| Earnings | -US$72.97m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | 58.31% |
| Net Profit Margin | -61.32% |
| Debt/Equity Ratio | 0% |
How did BBNX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 22:42 |
| End of Day Share Price | 2026/09/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beta Bionics, Inc. is covered by 15 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Travis Steed | BofA Global Research |
| David Roman | Goldman Sachs |